Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

Vaccine. 2010 Oct 21;28(45):7306-12. doi: 10.1016/j.vaccine.2010.08.077. Epub 2010 Sep 16.


We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell responses. Using IFN-γ Elispot assays, we observed new or increased responses to MVA virus in 52% of HIV-seronegative subjects and 93% HIV-1 seropositive subjects; MVA-specific T cell frequencies were generally low and correlated poorly with T cell responses to the HIV-1 immunogen. In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens.

Publication types

  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • Adolescent
  • Adult
  • Antiretroviral Therapy, Highly Active
  • Epitopes, T-Lymphocyte / immunology
  • Genetic Vectors
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Seronegativity
  • HIV-1 / immunology
  • Humans
  • Immunity, Cellular
  • Immunization, Secondary
  • Interferon-gamma / immunology
  • Middle Aged
  • T-Lymphocytes / immunology*
  • Vaccinia virus / immunology*
  • Young Adult


  • AIDS Vaccines
  • Epitopes, T-Lymphocyte
  • Interferon-gamma